Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Radiation for High Risk Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologic diagnosis of urothelial or squamous cell carcinoma of the bladder~* Patients must have undergone cystectomy (total cystectomy, radical cystectomy +/- pelvic lymph node dissection) with no evidence of macroscopic residual disease~* Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status of 0-2~* Patients treated with simple cystectomy with macroscopically negative margins are eligible for this study~* Clinical T-stage (prior to systemic therapy, if applicable) ≥ T3a and/or positive lymph nodes by transurethral resection of bladder tumor (TURBT)/magnetic resonance imaging (MRI)/computed tomography (CT)/positron emission tomography (PET)-CT or pathologic T-stage ≥ T3a and/or positive lymph nodes~Exclusion Criteria:~* Patients with metastatic disease outside of the pelvis~* Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years~* Prior radiation therapy to the pelvis~* Patients with active inflammatory bowel disease~* Severe acute co-morbidity, defined as follows:~  * Unstable angina and/or congestive heart failure requiring hospitalization in the last 3 months~ * Transmural myocardial infarction within the last 6 months~ * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration~ * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration~ * Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatment involved in this protocol may be significantly immunosuppressive; protocol-specific requirements may also exclude immunocompromised patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3D conformal radiation therapy (Type: EXPERIMENTAL): Within 24 weeks of surgical resection, patients undergo conformal radiation therapy once daily 5 days per week for 28 fractions. Treatment continues in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).